Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2025
Emerging Company Profile
Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy
With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
BioCentury | Feb 27, 2025
Distillery Therapeutics
Single-dose vaccine for Zika without enhancement of dengue
BioCentury | Feb 12, 2025
Discovery & Translation
Pain targets in ion channel pathways: an Innovation Distillery spotlight
Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets
BioCentury | Jan 28, 2025
Distillery Therapeutics
Monoclonal antibodies blocking malaria binding to host EPCR
BioCentury | Dec 19, 2024
Emerging Company Profile
Ottimo: Differentiating from the VEGF bispecific pack via VEGFR-2
Newco, led by ex-Seagen CEO Epstein, announces $140M series A
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | Jul 18, 2024
Data Byte
New AMD data showcase the promise and high bar for vectorized biologics
Two gene therapies reduced the need for VEGF injections, but just the suggestion of imperfect safety sent shares of one company tumbling
Items per page:
1 - 10 of 1202